Request an invite

Besponsa: which tox species, and why?

inotuzumab ozogamicin · CD22
Species
Rat and cynomolgus monkey (neither cross-reactive; target-independent toxicity only)
“The Applicant conducted repeat-dose toxicity studies of up to 6 months duration in rats and cynomolgus monkeys to investigate the chronic toxicity of inotuzumab ozogamicin;”
✓ VerifiedFDA multi-discipline review, p. 34Source ↗
Why that species
No relevant species: G544 does not bind mouse, rat, rabbit or monkey B cells; tox limited to payload-driven, target-independent effects
“G544 did not bind B cells from mouse, rat, rabbit, or cynomolgus monkey whole blood, or granulocytes, MONO, or T cells from any species evaluated, including humans.”
✓ VerifiedFDA multi-discipline review, p. 36Source ↗
Surrogate molecule
No surrogate; clinical ADC in non-binding species, plus non-binding calicheamicin ADC (PF-06647259) investigative monkey study
“This study evaluated the target-independent toxicities of antibody-calicheamicin conjugates using a humanized nonbinding IgG1 monoclonal antibody conjugated to calicheamicin via the acid-labile AcBut linker (PF-06647259).”
✓ VerifiedFDA multi-discipline review, p. 53Source ↗

Same question, other ADCs

Adcetris

brentuximab vedotin · CD30
Rat and cynomolgus monkey (monkey the antigen-binding species)

Datroway

datopotamab deruxtecan · Trop-2
Rat (non-binding) and cynomolgus monkey (relevant); DXd payload in rat and monkey

Decnupaz

pivekimab sunirine · CD123
Cynomolgus monkey (no CD123 cross-reactivity; off-target/payload toxicity) plus rat for FGN849 payload

Elahere

mirvetuximab soravtansine · FRα
Cynomolgus monkey (general tox); rabbit for ocular tox; DM4 payload in monkey and mouse

Emrelis

telisotuzumab vedotin · c-Met
Cynomolgus monkey (relevant); rat non-binding (exploratory, MMAE-related effects)

Enhertu

fam-trastuzumab deruxtecan · HER2
Cynomolgus monkey (relevant) plus rat (non-binding species)

Kadcyla

ado-trastuzumab emtansine · HER2
Rat and cynomolgus monkey (monkey pharmacologically relevant; long-term studies in monkey)

Mylotarg

gemtuzumab ozogamicin · CD33
Rat and cynomolgus monkey (neither pharmacologically relevant; no CD33 cross-reactivity)

Padcev

enfortumab vedotin · Nectin-4
Rat and cynomolgus monkey

Polivy

polatuzumab vedotin · CD79b
Rat and cynomolgus monkey (monkey with clinical ADC plus monkey-CD79b surrogate ADC)

Tivdak

tisotumab vedotin · Tissue factor
Cynomolgus monkey only for ADC; rat and monkey for MMAE payload

Trodelvy

sacituzumab govitecan · Trop-2
Cynomolgus monkey only (mouse for target-independent toxicity only)

Zynlonta

loncastuximab tesirine · CD19
No pharmacologically relevant species; cynomolgus monkey (non-binding) for ADC; rat and dog for payload SG3199

Summary across all 14 ADCs →